IRIS
ASCARI, EDOARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.586
AS - Asia 3.766
EU - Europa 2.993
SA - Sud America 409
AF - Africa 91
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 7
Totale 11.864
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.494
CN - Cina 2.035
SG - Singapore 780
IE - Irlanda 692
UA - Ucraina 470
HK - Hong Kong 367
FI - Finlandia 366
DE - Germania 349
BR - Brasile 314
RU - Federazione Russa 290
SE - Svezia 272
VN - Vietnam 248
FR - Francia 164
GB - Regno Unito 157
IT - Italia 114
IN - India 96
CA - Canada 57
ZA - Sudafrica 46
AR - Argentina 39
BD - Bangladesh 32
IQ - Iraq 25
JP - Giappone 23
NL - Olanda 23
BE - Belgio 19
IR - Iran 17
PL - Polonia 17
ID - Indonesia 16
VE - Venezuela 16
MX - Messico 15
PK - Pakistan 15
ES - Italia 14
SA - Arabia Saudita 13
CO - Colombia 12
EC - Ecuador 12
UZ - Uzbekistan 12
AU - Australia 11
TR - Turchia 11
JO - Giordania 10
MA - Marocco 10
AT - Austria 8
DZ - Algeria 8
KE - Kenya 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
PH - Filippine 7
CZ - Repubblica Ceca 6
DK - Danimarca 6
EG - Egitto 6
PY - Paraguay 6
CL - Cile 5
NP - Nepal 5
AZ - Azerbaigian 4
CR - Costa Rica 4
EU - Europa 4
HR - Croazia 4
IL - Israele 4
LB - Libano 4
PS - Palestinian Territory 4
RO - Romania 4
BH - Bahrain 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GE - Georgia 3
GR - Grecia 3
KZ - Kazakistan 3
LT - Lituania 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
CY - Cipro 2
JM - Giamaica 2
KG - Kirghizistan 2
KR - Corea 2
LK - Sri Lanka 2
ML - Mali 2
MU - Mauritius 2
NI - Nicaragua 2
OM - Oman 2
RS - Serbia 2
SV - El Salvador 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
CH - Svizzera 1
CI - Costa d'Avorio 1
GT - Guatemala 1
HN - Honduras 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
Totale 11.862
Salva come PNG Salva come JPEG
Città #
Dublin 689
Chandler 591
Jacksonville 570
San Jose 529
Nanjing 455
Singapore 393
Ashburn 359
Hong Kong 356
Beijing 294
Dallas 291
Boardman 202
Nanchang 191
Princeton 137
Shenyang 126
Hebei 125
Lawrence 125
Medford 121
Changsha 114
Wilmington 112
Los Angeles 110
Lauterbourg 104
Jiaxing 99
Helsinki 92
Ann Arbor 77
Ho Chi Minh City 77
Tianjin 74
Hangzhou 72
Munich 70
New York 62
Hanoi 58
Moscow 57
Buffalo 49
Shanghai 44
Milan 43
Redondo Beach 43
Johannesburg 40
Turku 37
Woodbridge 33
Norwalk 28
São Paulo 28
Verona 24
Montreal 23
Orem 23
Tokyo 22
Toronto 21
Seattle 20
Chicago 19
Fairfield 19
Brussels 18
Santa Clara 17
Denver 15
Guangzhou 15
Houston 15
Warsaw 15
Haiphong 13
Kunming 13
Manchester 13
Brooklyn 12
Da Nang 12
San Francisco 12
Chennai 11
Frankfurt am Main 11
Jinan 11
London 11
Phoenix 11
Zhengzhou 11
Boston 10
Brasília 10
Des Moines 10
The Dalles 10
Auburn Hills 9
Falkenstein 9
Poplar 9
Tashkent 9
Atlanta 8
Baghdad 8
Nairobi 8
Ningbo 8
Piscataway 8
Rio de Janeiro 8
San Genesio Ed Uniti 8
Taizhou 8
Amsterdam 7
Belo Horizonte 7
Mumbai 7
New Delhi 7
Quito 7
Amman 6
Changchun 6
Columbus 6
Delhi 6
Falls Church 6
Jeddah 6
Mexico City 6
Orange 6
Rome 6
Andover 5
Ardabil 5
Bắc Ninh 5
Campinas 5
Totale 7.733
Salva come PNG Salva come JPEG
Nome #
A combination regimen of idarubicin and cytosine arabinoside for patients with high-risk myelodysplastic syndromes 165
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 157
5' Nucleotidase in chronic B cell leukemias: a cytochemical and ultrastructural study 154
[Biochemical modifications of the erythrocyte membrane in various red cell disorders] 138
[Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons] 138
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 137
Acute promyelocitic leukemia toluidine blue subtype. 135
Anomalous erythrocytes produced by rabbits with liver damage. 134
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils:inhibition of amyloidogenesis. 133
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 127
Severe platelet disfunction in a patient with autoantibodies against membrane glycoproteins IIb-IIIa 127
Acute phase proteins and prognosis in multiple myeloma. 124
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol 123
AMYLOIDOSIS AL 121
Ageing of rabbit red cells in vitro: membrane modifications and their possible role in red cell survival in vivo. 121
Cytokinetic changes in the peripheral blood of leukemic patients during cytostatic therapy. VI. Effect of arabinosylcytosine. 120
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. 118
A further case of myeloproliferative syndrome with reciprocal translocation (8;13)(p11;q12) 118
- Hematological values from quantitative buffy coat analysis (QBC II) system: evaluation in an hematological/oncological outpatient section 117
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 116
A plea to overcome th concept of "staging" and related inadequacy in multiple myeloma. 114
[Glycoproteins of the erythrocyte membrane in normal and pathological conditions] 114
A prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma. 113
Acquired immune thrombastenia: a new bleeding disorder. 113
The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. 113
Advanced breast cancer: a randomized study of different doses of epirubicin associated with fixed doses of cyclophosphamide and 5-fluorouracil. 111
[Prophylaxis and therapy of neuro-meningeal involvement of acute lymphoblastic leukemia. Case reports and critical review of literature (author's transl)] 111
Acquired cyclic thrombocytopenia-thrombocytosis with periodic defect of platelet function. 110
The clinical value of tumor burden at diagnosis in Hodgkin lymphoma 109
Silymarine during maintenance therapy of acute promyelocytic leukemia. 108
Possible evolution of human parvovirus B19 infection into erythroleukemia 107
Anemie megaloblastiche. 107
On the usefulness of PAS reaction for the prognosis of acute lymphoblastic leukemia. 107
Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. 106
Effetti sistemici della terapia trombolitica.[Systemic effects of thrombolytic therapy]. 106
Reactive hemophagocytosis in Ki-1 positive largeb cell lymphoma: a case study. 104
A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma. 104
[Pure acute monocytic leukaemia: morphological, cytochemical and clinical study of 14 cases (author's transl)]. 104
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 103
IMMUNOENZYMATIC DETECTION OF PROTEINS TRANSFERRED ON NITROCELLULOSE AFTER FIXATION AND STAINING IN POLYACRYLAMIDE GEL 102
Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome 101
Response to cyclosporin A and rhG-CSF in a case of aplastic anemia. 101
CHARACTERIZATION OF ANTI-STREPTOLYSIN O ACTIVITY OF A HUMAN MONOCLONAL IgG LAMDA. 101
Changing clinical presentation of multiple myeloma. 99
High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. 99
Presentation features of monoclonal gammopathies: analysis of 684 newly diagnosed cases. 98
[Chronic granulomatous disease with sea-blue histiocytosis: a case report (author's transl)]. 98
Intravenous prostacyclin (as epoprostenol) infusion in thrombotic thrombocytopenic purpura. Four case reports and review of the literature. Italian Cooperative Group for Thrombotic Thrombocytopenic Purpura 98
Membrane CD22 defines circulating myeloma-related cells as mature or later B cells 97
Clinical relevance of two in vitro tests based on CFU-GM assay in the study of granulopoietic failure 97
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy: cytokinetic effects on bone marrow hematopoietic progenitors. 95
Biologia e clinica del mieloma multiplo. 95
Significance of marrow-blood barrier for CFU-GM in patients with acute nonlymphoid leukemia (AnLL) 95
STUDY OF THREE PATIENTS WITH MONOCLONAL GAMMAPATHIES AND "LUPUS-LIKE" ANTICOAGULANTS. 94
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis 94
Osteonecrosi avascolare del massiccio facciale in corso di terapia con bisfosfonati [Avascular jaw osteonecrosis associated with bisphophonate therapy]. 94
Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP 94
Effects of desferrrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies 93
The effect of red blood cells on platelet aggregation; a study with the whole blood aggregometer 93
Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. 93
Acute non-lymphoblastic leukemia. Correlation between clinical and hematological parameters in 87 adult patients. 93
RELEVANCE OF CLASS, MOLECULAR WEIGHT AND ISOELECTRIC POINT IN PREDICTING HUMAN LIGHT CHAIN AMYLOIDOGENICITY. 91
Fisiopatologia dell'eritrocito. 91
Sequential vincristine, arabinosylcytosine and daunomycin in acute leukemia: a preliminary report. 91
Cancer chemotherapy-related thrombotic thrombocytopeic purpura: biological evidence of increased nitric oxide production. 90
CYCLIC THROMBOCYTOPENIA-THROMBOCYTOSIS WITH A PERIODIC DEFECT OF PLATELET-FUNCTION - REPORT OF A CASE 89
Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes 89
Lymphocyte reactivity in chronic lymphocytic leukaemia: effect of repeated and prolonged stimulation with PHA and PWM. 89
The syndrome of abnormal chromatin clumping in leucocytes: clinical and biological study of a case. 89
Glycopeptides of erythrocyte membranes in some hematological disorders 88
Expression of p53, bcl-2 and ras oncoproteins in acute leukemias and myelodysplastic syndromes 88
Chemotherapy-induced leukonychia 88
Left ventricular function in colon cancer patients receiving adjuvant fluoro-folate chemotherapy. An echocardiographic study. 87
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis 87
Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian Cooperative Group for TTP 87
International prognostic scoring system and other prognostic systems for myelodysplastic syndromes. 86
Applicazioni cliniche dei fattori di crescita emopoietici. 85
Cell cycle status and apoptosis of hematopoietic progenitor cells released into the peripheral blood after taxanes anf granulocyte colony-stimulating factor in breast cancer patients 84
Surface mechanisms of platelet adhesion and aggregation 84
Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP 84
Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry 83
Acute promyelocytic leukemia: morphological and clinical features. 83
In vivo behaviour of neuraminidase-treated rabbit erythrocytes and reticulocytes 81
Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high risk myelodysplastic syndromes 81
Tetrahydrofolate dehydrogenase cytochemistry in acute lymphoblastic leukemia. 80
Applicazioni cliniche della citometria. 80
Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study. 80
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. 80
Structural modifications in membrane glycoproteins during the erythrocyte life-span. 79
Behaviour of young and old desialylated rabbit erythrocytes in vivo. 79
IL MIELOMA MULTIPLO 79
Establishment and characterization of a B-cell line derived from a patient with a myelodysplastic syndrome which expresses myelomonocytic and lymphoid markers. 78
Loss of the Y chromosome in smoldering acute leukemia. 78
Bone marrow morphology and proliferative activity in acquired immunodeficiency syndrome. 78
Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony stimulating factor. 77
Terapia del mieloma multiplo. 77
Membrane sialic acid and behaviour in vivo of rabbit "stress" macroreticulocytes. 76
Erythrocyte membrane modifications in chronic granulocytic leukaemia 75
Flow cytometric analysis of multidrug resistance antigen (p glicoprotein) and DNA ploidy in human colon cancer 74
Cytokinetic studies on circulating neoplastic cells of Hodgkin's disease. 74
Totale 10.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.512
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.512
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021154 0 0 0 0 0 0 0 0 0 0 117 37
2021/2022650 9 1 21 10 24 35 12 35 23 32 88 360
2022/20231.811 217 129 21 136 183 174 0 85 777 9 54 26
2023/2024550 80 92 25 59 51 133 15 32 7 14 25 17
2024/20251.566 44 142 37 52 25 49 53 109 391 47 183 434
2025/20263.771 275 254 441 523 421 220 809 135 343 278 72 0
Totale 11.938